LAGOON Trial: Zepzelca Fails to Improve Survival in Second-Line SCLC

Jazz Pharmaceuticals reported top-line Phase 3 LAGOON results in relapsed (second-line) small cell lung cancer showing Zepzelca (lurbinectedin) as monotherapy or with irinotecan did not improve overall survival vs investigators' choice (topotecan or irinotecan). Safety was consistent with known profiles. The findings do not affect Zepzelca's first-line maintenance approval from IMforte and Jazz will discuss next steps with the FDA for the second-line indication; results varied by CNS involvement with no OS benefit in the overall population.